Navigation Links
BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
Date:2/29/2012

LYNBROOK, N.Y., Feb. 29, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that BioSpecifics' President, Tom Wegman, will present at the following upcoming investor conferences during the month of March 2012.

  • Cowen and Company 32nd Annual Health Care Conference (Boston, MA)
    Wednesday, March 7, 2012 at 10:40 a.m. EST
  • ROTH Capital Partners 24th Annual Conference (Laguna Niguel, CA)
    Tuesday, March 13, 2012 at 3:30 p.m. PDT (6:30 p.m. EDT)

The live webcasts of these presentations can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Its partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture in adults with a palpable cord in the palm and is also developing XIAFLEX for the treatment of Peyronie's disease, which is currently in Phase 3 pivotal clinical trials, as well as for Frozen Shoulder (Adhesive Capsulitis) and cellulite which are in Phase 2 and Phase 1 respectively. Pfizer, Inc. is responsible for marketing XIAPEX® for Dupuytren's contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie's disease in these same territories. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan and Actelion Pharmaceuticals has the development, supply and commercialization rights in Canada, Australia, Brazil and Mexico. BioSpecifics is developing XIAFLEX internally for human and canine lipomas. More information about the Company may be found on its website at www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2011 Financial Results on November 8, 2011
3. BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting
4. BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results
5. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results
6. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2010 Financial Results on March 11, 2011
7. BioSpecifics Technologies Corp. to Present at Cowen and Company 31st Annual Health Care Conference
8. BioSpecifics Announces Positive Results From Clinical Trial in Canine Lipomas
9. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
10. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
11. Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Lincoln, NE (PRWEB) , ... December 07, 2016 ... ... control systems integration, today announced that it has become a Wonderware Certified System ... Wonderware System Integrator Partner by Schneider Electric Software. , “The System Integrator Partner ...
(Date:12/7/2016)... OTTAWA, Ontario , Dec. 7, 2016 /PRNewswire/ ... partnership with General Atomics (GA), welcome today,s award ... National Nuclear Security Administration (NNSA) of the Phase ... its project with Nordion and the University of ... Phase II funding will support the establishment of ...
(Date:12/7/2016)... Dec. 7, 2016  Genprex, Inc. a biopharmaceutical ... therapy treatments, today announced that it has retained ... leading strategic communications and advisory firm, to develop ... program will combine investor relations, public relations and ... the profile of Genprex and its lead candidate ...
(Date:12/7/2016)... Boston, MA and Azusa, CA (PRWEB) , ... ... ... commercial provider of distributed wastewater treatment and resource recovery solutions for industrial facilities, ... Brewing Company , will be the first to use Cambrian’s novel water-energy purchase ...
Breaking Biology Technology:
(Date:11/28/2016)... 2016 "The biometric system ... The biometric system market is in the growth ... near future. The biometric system market is expected to ... a CAGR of 16.79% between 2016 and 2022. Government ... technology in smartphones, rising use of biometric technology in ...
(Date:11/19/2016)... 2016 Securus Technologies, a leading provider of ... investigation, corrections and monitoring, announced today that it has ... have an independent technology judge determine who has the ... tech/sophisticated telephone calling platform, and the best customer service. ... most of what we do – which clearly is ...
(Date:11/15/2016)... Nov 15, 2016 Research and Markets has ... to 2021" report to their offering. ... ... Billion by 2021 from USD 6.21 Billion in 2016, growing at ... Growth of the bioinformatics market is driven by the growing demand ...
Breaking Biology News(10 mins):